US Patent 9,238,040
United States Patent and Trademark Office
Rutgers, the State University of New Jersey (New Brunswick, NJ, US) ; University of Iowa Research Foundation (Iowa City, IA, US)
A method for preventing colorectal cancer in a patient possessing human tropomyocin isoform TC22 is disclosed. The method comprises: (a) detecting a serum protein concentration of TC22 in a patient and (b) administering to said patient prior to detecting colorectal cancer in said patient a therapeutically effective amount of a chemotherapeutic composition comprising a chemotherapeutic compound that reduces the level of TC22, wherein the chemotherapeutic compound is selected from the group consisting of sulfasalazine, 5-amino-2-hydroxybenzoic acid, osalazine, and balsalazide.
Das, Kiron M. and Lin, Jim Jung-ching Chemoprevention of colorectal cancer by mesalamine/sulfasalazine. US Patent 9,238,040 filed May 17, 2006 and issued January 19, 2016. https://ir.uiowa.edu/patents/652